Filing Details
REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) filed a Form 8-K with the Securities and Exchange Commission on July 06, 2026, disclosing a material event.
8k filedNASDAQ:REGN
REGENERON PHARMACEUTICALS, INC. (REGN) Reports Material Event to SEC
Filing Details REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) filed a Form 8-K with the Securities and Exchange Commission on July 06, 2026, disclosing a material event. Market…
Market Context
REGENERON PHARMACEUTICALS, INC.'s stock currently trades at $649.81 with a market capitalization of $77.2B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for REGENERON PHARMACEUTICALS, INC.'s stock.
All SEC filings for REGENERON PHARMACEUTICALS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View REGN Stock Page
Frequently Asked Questions
Where can I read REGN's SEC filings?
Browse all filings on our REGN SEC filings page.
What types of SEC filings does REGENERON PHARMACEUTICALS, INC. file?
Public companies like REGENERON PHARMACEUTICALS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
